Maze Therapeutics (MAZE) Income towards Parent Company (2024 - 2026)
Maze Therapeutics (MAZE) posted Income towards Parent Company of -$19.6 million for Q1 2026, down 178.62% sequentially from -$7.0 million in Q4 2025, and up 40.23% YoY from -$14.0 million in Q1 2025.
Maze Therapeutics (MAZE) Income towards Parent Company (2024 - 2026) Analysis & Trends
Maze Therapeutics has reported Income towards Parent Company for 3 years, with the latest figure at -$19.6 million in Q1 2026.
- Quarterly Income towards Parent Company rose 40.23% year-over-year to -$19.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$90.4 million (down 315.65% YoY) and the FY2025 annual result came in at -$103.6 million, down 345.53% from the prior year.
- Income towards Parent Company retreated to -$19.6 million in Q1 2026 per MAZE's latest filing, from -$7.0 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at $139.1 million in Q2 2024 and troughed at -$39.6 million in Q4 2024.
- A 3-year average of -$8.5 million and a median of -$27.7 million in 2024 frame the typical range for Income towards Parent Company.
- The widest YoY moves for Income towards Parent Company: up 82.25% in 2025, down 124.22% in 2025.
- Over 3 years, Income towards Parent Company stood at -$39.6 million in 2024, then soared by 82.25% to -$7.0 million in 2025, then slumped by 178.62% to -$19.6 million in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods registered -$19.6 million, -$7.0 million, and -$30.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Maze Therapeutics | 1.51 Bn | 1.51 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -40.18 Mn |
| Mar 31, 2026 | -19.60 Mn |
| Dec 31, 2025 | -7.03 Mn |
| Sep 30, 2025 | -30.09 Mn |
| Jun 30, 2025 | -33.68 Mn |
| Mar 31, 2025 | -32.79 Mn |
| Dec 31, 2024 | -39.62 Mn |
| Sep 30, 2024 | -24.73 Mn |
| Jun 30, 2024 | 139.06 Mn |
| Mar 31, 2024 | -27.73 Mn |